Replaces Prod. #: ALX-270-355
Antidiabetic thiazolidinedione. Potent and selective PPARγ ligand. Binds to the PPARγ ligand-binding domain and recruits ligand-specific transcriptional coactivators at 1µM. In skeletal muscle and adipocyte cell cultures, the EC50 of troglitazone is about 10µM. Displaces [125I]SB-236636 with an IC50=7.9µM. Stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. Induces apoptosis in human vascular smooth muscle cells and inhibits the growth of a variety of human cancer cells including lung, bladder and myeloid leukemia cells. Displays an anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization.
Product Details
| Alternative Name: | (±)-5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione |
| |
| Formula: | C24H27NO5S |
| |
| MW: | 441.5 |
| |
| Source: | Synthetic. |
| |
| CAS: | 97322-87-7 |
| |
| MI: | 14: 9769 |
| |
| RTECS: | XJ5813130 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to yellow solid. |
| |
| Solubility: | Soluble in DMSO (>25mg/ml), 100% ethanol (>25mg/ml, warm) or dimethyl formamide. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at +20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Technical Info/Product Notes: | Troglitazone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, troglitazone should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Troglitazone has a solubility of 100µg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Note: Product is not sterile. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The urinary metabolites of DINCH® have an impact on the activities of the human nuclear receptors ERα, ERβ, AR, PPARα and PPARγ: A. Engel, et al.; Toxicol. Lett.
287, 83 (2018),
Abstract;
Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro: J. Ye, et al.; Onco. Targets Ther.
8, 1211 (2015),
Application(s): Cell Culture, Assay,
Abstract;
Full Text
Fatty acids increase adiponectin secretion through both classical and exosome pathways: V. DeClercq, et al.; Biochim. Biophys. Acta
1851, 1123 (2015),
Application(s): Cell Culture,
Abstract;
15-Deoxy-{delta}12,14-prostaglandin j2 inhibits interleukin-1{beta}-induced nuclear factor-{kappa}b in human amnion and myometrial cells: mechanisms and implications: T.M. Lindström & P.R. Bennett; J. Clin. Endocrinol. Metab.
90, 3534 (2005),
Abstract;
Full Text
Enhancing effect of troglitazone on porcine adipocyte differentiation in primary culture: a comparison with dexamethasone: Y.D. Tchoukalova, et al.; Obes. Res.
8, 664 (2000),
Abstract;
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis: Y. Tsubouchi, et al.; BBRC
270, 400 (2000),
Abstract;
Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators: Y. Kodera, et al.; J. Biol. Chem.
275, 33201 (2000),
Abstract;
Full Text
Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci.
67, 2405 (2000),
Abstract;
Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells: T. Okura, et al.; Eur. J. Pharmacol.
407, 227 (2000),
Abstract;
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death: Y.F. Guan, et al.; Neoplasia
1, 330 (1999),
Abstract;
Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids: H. Asou, et al.; Int. J. Oncol.
15, 1027 (1999),
Abstract;
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma: P.W. Young, et al.; J. Pharmacol. Exp. Ther.
284, 751 (1998),
Abstract;
General Literature References
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones: T.M. Willson, et al.; J. Med. Chem.
39, 665 (1996),
Abstract;
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem.
270, 12953 (1995),
Abstract;
Full Text
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem.
37, 3977 (1994),
Abstract;
